Страна: Европейски съюз
Език: английски
Източник: EMA (European Medicines Agency)
Anagrelide hydrochloride
Mylan Pharmaceuticals Limited
L01XX35
anagrelide
Antineoplastic agents
Thrombocythemia, Essential
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.
Revision: 8
Authorised
2018-02-15
23 B. PACKAGE LEAFLET 24 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ANAGRELIDE VIATRIS 0.5 MG HARD CAPSULES anagrelide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Anagrelide Viatris is and what it is used for 2. What you need to know before you take Anagrelide Viatris 3. How to take Anagrelide Viatris 4. Possible side effects 5. How to store Anagrelide Viatris 6. Contents of the pack and other information 1. WHAT ANAGRELIDE VIATRIS IS AND WHAT IT IS USED FOR Anagrelide Viatris contains the active substance, anagrelide. Anagrelide is a medicine which interferes with the development of platelets. It reduces the number of platelets produced by the bone marrow, which results in a decrease in the platelet count in the blood towards a more normal level. For this reason, it is used to treat patients with essential thrombocythaemia. Essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of the blood cells known as platelets. Large numbers of platelets in the blood can cause serious problems with blood circulation and clotting. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ANAGRELIDE VIATRIS DO NOT TAKE ANAGRELIDE VIATRIS • If you are allergic to anagrelide or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may be recognised as a rash, itching, swollen face or lips, or shortness of breath; • If you have moderate or severe liver problems; • If you have moderate or severe kidney problems. WARNINGS AND PRECAUTIONS Talk to yo Прочетете целия документ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Anagrelide Viatris 0.5 mg hard capsules Anagrelide Viatris 1 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Anagrelide Viatris 0.5 mg hard capsules Each hard capsule contains anagrelide hydrochloride monohydrate equivalent to 0.5 mg anagrelide. _Excipients with known effect _ Each hard capsule contains approximately 59.5 mg lactose. Anagrelide Viatris 1 mg hard capsules Each hard capsule contains anagrelide hydrochloride monohydrate equivalent to 1 mg anagrelide. _Excipients with known effect _ Each hard capsule contains approximately 119 mg lactose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule (capsule). Anagrelide Viatris 0.5 mg hard capsules A capsule size 4 (approximately 14.3 x 5.3 mm) with an opaque white body and cap. The capsule is filled with white to off-white powder. Anagrelide Viatris 1 mg hard capsules A capsule size 4 (approximately 14.3 x 5.3 mm) with a grey body and cap. The capsule is filled with white to off-white powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET patient is defined by one or more of the following features: • > 60 years of age or • a platelet count >1,000 x 10 9 /l or • a history of thrombo-haemorrhagic events. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION 3 Treatment with anagrelide should be initiated by a clinician with experience in the management of ET. Posology The recommended starting dose of anagrelide is 1 mg/day, which should be administered orally in two divided doses (0.5 mg/dose). The starting dose should be maintained for at least one week. After one week the dose may be titrated, on an individual basis, to achieve the lowest eff Прочетете целия документ